Our Pipeline
We are advancing an oncology pipeline with three programs in clinical development: tamibarotene (formerly SY-1425), a first-in-class selective oral RARα agonist for genomically defined subsets of patients with higher-risk myelodysplastic syndrome and acute myeloid leukemia; SY-2101, a novel oral form of arsenic trioxide for patients with acute promyelocytic leukemia; and SY-5609, a highly selective and potent oral CDK7 inhibitor for patients with pancreatic cancer and BRAF-mutant colorectal cancer. We also have programs in earlier stages of research and development in oncology.
View Programs